EMG
TVRD

Ellington Management Group’s Tvardi Therapeutics TVRD Stock Holding History

Ellington Management Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,594
Closed -$780K – 845
2016
Q3 		$780K Buy
+2,594
New +$562K 0.21% 124
2016
Q2 		– Sell
-381
Closed -$85K – 515
2016
Q1 		$85K Buy
+381
New +$114K 0.04% 474

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ellington Management Group's TVRD Position: Q4 2016 in Review

Ellington Management Group sold out of Tvardi Therapeutics (TVRD) in Q4 2016, closing a stake of 2,594 shares — an estimated $780K sold.

Ellington Management Group first reported a position in TVRD in Q1 2016 and held it in 2 quarters. The position peaked at $780K in Q3 2016. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

  • Ellington Management Group reported no remaining Tvardi Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Ellington Management Group sold 2,594 Tvardi Therapeutics shares in Q4 2016, an estimated $780K.
  • Ellington Management Group first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 2 quarters.
  • Ellington Management Group's Tvardi Therapeutics position peaked at $780K in Q3 2016.
  • 101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on Ellington Management Group's 13F filing for Q4 2016, filed 14 Feb 2017.